WO2006062434A1 - Modified 5'- phosphonate azidothymidine-potential anti-viral preparations - Google Patents
Modified 5'- phosphonate azidothymidine-potential anti-viral preparations Download PDFInfo
- Publication number
- WO2006062434A1 WO2006062434A1 PCT/RU2005/000249 RU2005000249W WO2006062434A1 WO 2006062434 A1 WO2006062434 A1 WO 2006062434A1 RU 2005000249 W RU2005000249 W RU 2005000249W WO 2006062434 A1 WO2006062434 A1 WO 2006062434A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- azt
- azido
- groups
- azidothymidine
- phosphonate
- Prior art date
Links
- 0 *C1C(CO)OC(*)C1 Chemical compound *C1C(CO)OC(*)C1 0.000 description 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Definitions
- Modified AZT 5'-phosphonates are potential antiviral drugs.
- the invention relates to the field of molecular biology, virology and medicine, namely, to new derivatives of nucleosides, namely to substituted 5'-phosphates of AZT. These compounds have an antiviral effect and can be used to suppress the reproduction of the human immunodeficiency virus.
- nucleoside and non-nucleoside inhibitors are distinguished.
- nucleoside derivatives the most commonly used are Z'-azido-Z'-deoxythymidine (AZT, Zidovudine®), 2 ', 3'-didesoxycycididine (ddC, Zalcitabine®), 2', 3'-didezoxyhydroxyinosine (ddl, Didanosine® ), 2 ', 3'-dideoxy-2', 3'-didehydro-thymidine (d4T, Stavudin®) and 2 ', 3'-dideoxy-3'-thiacytidine (3TC, Lamivudin®) [De ⁇ concession batterqu, E., 2002 .New development and ip apti-ShV scheoteraru. BIOSHIT. Biorhus. Assa, 1587 258-275].
- N-phosphonate AZT (Nikavir®), approved in Russia for the treatment of AIDS, is less toxic than AZT [Iptracacellular metabolism and appharmacophosphate 5f-hydrophosphate ap 3f-azido-2 ', 3diridephide Of Z'-azido-g ⁇ Z'-dideohuhutididpe. Aptiviral Resource 63 (2004), 107-113].
- the action of Nikavir is based on the ability to release AZT, which after intracellular conversion to AZT-5'-triphosphate inhibits HIV replication.
- Nikavir According to pharmacokinetic studies, the clinical benefits of Nikavir are explained by a slower and smoother increase in the concentration of AZT in the blood than when taking AZT itself; wherein C max AZT from Nikavir ⁇ C max AZT from Zidovudine, and T w AZT from Nikavir> T 1/2 AZT from Zidovudin [Y. Skolov et al. / Apptiviral Resecarch 63 (2004) 107-113].
- the toxicity of Nikavir remains quite high. Another disadvantage is the emergence of resistance to Nikavir.
- This invention solves the problem of creating low toxic derivatives of AZT, with the ability to penetrate into the cell and gradually release the active nucleoside (AZT). This will maintain an intracellular concentration of the drug sufficient for the manifestation of a therapeutic effect for a long time and, thus, reduce a single dose of the drug and / or frequency of administration and reduce side effects.
- R alkyl groups, including those containing halogen atoms, carboxy, hydroxy, alkoxy and acyloxy groups, as well as substituted amino carbonyl groups.
- the new compounds inhibit the reproduction of type 1 human immunodeficiency virus in a culture of transplantable MT-4 lymphocytes, protect the cells from the cytopathogenic effect of the virus, and do not show toxicity to host cells up to extremely high concentrations (Table 1). From the obtained experimental data, it can be seen that the tested compounds, without exerting toxic effects on cells at effective concentrations (50% toxic doses are 2-4 orders of magnitude higher than 50% inhibitory doses), inhibit the reproduction of type 1 immunodeficiency virus to a high degree in MT-4 cell culture.
- the therapeutic indices of the studied compounds (IS), defined as the ratio of the toxic dose of the drug to its effective dose, are comparable to those for AZT N-phosphonate. Virological tests are carried out in accordance with the previously described protocols.
- Target phosphonates were prepared as follows:
- the target fractions were evaporated, the residue was diluted with water (3 ml) and further purified on a LiChhorr RP-18 column, eluting with water.
- the solution was applied to a column with DEAE cellulose in an HCO 3 "form, eluting with a linear gradient of NH 4 HCO 3 (0—" -15 mM, pH 7.5).
- Target fractions were evaporated and re-evaporated with water (3 times 5 ml) , the residue was diluted with water (3 ml) and chromatographed on a column of LiChroper RP-18, eluting with water, and the target fraction was lyophilized to obtain 238 mg (66%) of phosphonate (Ic).
- ⁇ '-Methoxymethylphosphonyl-3'-azido-3'-deoxythymidine was synthesized from 3'-azido-3'-deoxythymidine and methoxymethylphosphonic acid according to the method described for compound Ic.
- a study of the inhibition of HIV reproduction involves culturing primary infected lymphoid cells of the MT-4 line in the presence of test compounds, the final concentrations of which in the culture medium are 0.001-100 ⁇ g / ml, over a passage of 4 days.
- Inhibition of HIV reproduction in a culture of sensitive cells is determined by a decrease in the accumulation of virus-specific protein p24 (according to enzyme-linked immunosorbent assay), as well as an increase in cell viability in the presence of the drug compared to the control determined on the 4th day of cultivation when stained with 3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide (MTT )
- the cytotoxicity of the drug is assessed by adding dilutions in serum-free RPMI-1640 medium to the MT-4 cell suspension, placed in the wells of a 96-night plate (Cell-Cult, Epglapd), to final concentrations of 0.001-100 ⁇ g / ml (three wells each) per dose), followed by cultivation at 37 ° C for 4 days.
- the inoculum concentration is 0.5 x 10 6 cell particles per milliliter.
- Cells are used as control without the addition of a drug, instead of which the same amount of serum free medium is added. Cell viability is counted on the 4th day of cultivation using the formazan method (intravital staining of MTT cells).
- the toxicity of various doses of the drug is determined by the viability of the cells relative to the control, a dose-dependent curve is constructed from the obtained results, and the concentration is determined that reduces cell viability by 50% (CD 50 ).
- the studied compounds do not have toxic effects on MT-4 cells in effective concentrations. It should also be noted that 50% of toxic doses are 5-6 orders of magnitude higher than those effective for HIV-1 doses (Table 1).
- the therapeutic index, or selectivity index (IS) is considered as the ratio of the 50% toxic concentration of the compound to its 50% effective dose (the results are presented in table 1). Based on these quantitative indicators of inhibition, one can judge the effectiveness of the antiviral effect of the claimed compounds, which consists in a high degree of suppression of HIV-1 replication in MT-4 cell culture, comparable to the efficiency of Nikavir.
- a dog weighing 12 kg was injected with 250 mg of the test substance orally (mixed with cottage cheese).
- blood samples (1 ml) were taken from the femoral vein.
- Samples were centrifuged (10 minutes, 2000 rpm), the supernatant was separated. Aliquots (0.25 ml) were taken from the supernatant, oxetane (0.25 ⁇ g as an internal standard) and methanol (0.75 ml) were added.
- the resulting mixture was centrifuged for 3 minutes at 5000 rpm.
- the supernatant was separated and evaporated in a stream of air at 40 0 C, water (1 ml) was added to the residue.
- the claimed compounds have low toxicity, are able to effectively inhibit the reproduction of type 1 immunodeficiency virus in a MT-4 cell culture and generate AZT in mammals, providing a smooth increase in its concentration in the blood.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05763842.1A EP1829885B1 (en) | 2004-11-25 | 2005-05-06 | Modified 5'- phosphonate azidothymidine-potential anti-viral preparations |
CN2005800467450A CN101115765B (zh) | 2004-11-25 | 2005-05-06 | 修饰的叠氮胸苷的5’-膦酸酯—潜在的抗病毒制剂 |
KR1020077013688A KR101323698B1 (ko) | 2004-11-25 | 2005-05-06 | Azt의 변형된 5'-포스포네이트 - 잠재적 항바이러스제 |
ES05763842.1T ES2550136T3 (es) | 2004-11-25 | 2005-05-06 | Preparaciones anti-víricas potenciales de 5'-fosfanato azidotimidina modificado |
US11/720,250 US7999099B2 (en) | 2004-11-25 | 2005-05-06 | Modified 5′-phosphonate azidothymidine—potential anti-viral preparations |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2004134388/04A RU2322450C2 (ru) | 2004-11-25 | 2004-11-25 | Модифицированные 5'-фосфонаты азт в качестве активных компонентов для потенциальных противовирусных препаратов |
RU2004134388 | 2004-11-25 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006062434A1 true WO2006062434A1 (en) | 2006-06-15 |
WO2006062434A8 WO2006062434A8 (fr) | 2007-11-01 |
Family
ID=36578174
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/RU2005/000249 WO2006062434A1 (en) | 2004-11-25 | 2005-05-06 | Modified 5'- phosphonate azidothymidine-potential anti-viral preparations |
Country Status (7)
Country | Link |
---|---|
US (1) | US7999099B2 (ru) |
EP (1) | EP1829885B1 (ru) |
KR (1) | KR101323698B1 (ru) |
CN (1) | CN101115765B (ru) |
ES (1) | ES2550136T3 (ru) |
RU (1) | RU2322450C2 (ru) |
WO (1) | WO2006062434A1 (ru) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013055252A1 (ru) | 2011-10-14 | 2013-04-18 | Закрытое Акционерное Общество " Производственно-Коммерческая Ассоциация Азт" | Соли эфиров карбомоилфосфоновой кислоты, являющиеся селективными ингибиторами продукции вируса иммунодефицита человека вич-1 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SU1548182A1 (ru) * | 1987-12-29 | 1990-03-07 | Институт молекулярной биологии АН СССР | 5 @ -Фосфонаты 3 @ -азидо-2 @ ,3 @ -дидезоксинуклеозидов, вл ющиес специфическими ингибиторами вируса СПИД в культуре лимфоцитов человека Н9/ШВ |
WO1991019727A1 (en) * | 1990-06-19 | 1991-12-26 | Sloan-Kettering Institute For Cancer Research | 5'-hydrogenphosphonates and 5'-methylphosphonates of sugar modified nucleosides, compositions and uses thereof |
WO1992000988A1 (en) * | 1990-07-13 | 1992-01-23 | Bodor Nicholas S | Targeted drug delivery via phosphonate derivatives |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4824850A (en) * | 1982-05-18 | 1989-04-25 | University Of Florida | Brain-specific drug delivery |
US4968788A (en) * | 1986-04-04 | 1990-11-06 | Board Of Regents, The University Of Texas System | Biologically reversible phosphate and phosphonate protective gruops |
US5002935A (en) * | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
JP2005525358A (ja) * | 2002-02-28 | 2005-08-25 | ビオタ インコーポレーティッド | ヌクレオチド模倣体およびそのプロドラッグ |
-
2004
- 2004-11-25 RU RU2004134388/04A patent/RU2322450C2/ru not_active Application Discontinuation
-
2005
- 2005-05-06 KR KR1020077013688A patent/KR101323698B1/ko not_active IP Right Cessation
- 2005-05-06 WO PCT/RU2005/000249 patent/WO2006062434A1/ru active Application Filing
- 2005-05-06 ES ES05763842.1T patent/ES2550136T3/es active Active
- 2005-05-06 CN CN2005800467450A patent/CN101115765B/zh not_active Expired - Fee Related
- 2005-05-06 EP EP05763842.1A patent/EP1829885B1/en not_active Expired - Fee Related
- 2005-05-06 US US11/720,250 patent/US7999099B2/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SU1548182A1 (ru) * | 1987-12-29 | 1990-03-07 | Институт молекулярной биологии АН СССР | 5 @ -Фосфонаты 3 @ -азидо-2 @ ,3 @ -дидезоксинуклеозидов, вл ющиес специфическими ингибиторами вируса СПИД в культуре лимфоцитов человека Н9/ШВ |
WO1991019727A1 (en) * | 1990-06-19 | 1991-12-26 | Sloan-Kettering Institute For Cancer Research | 5'-hydrogenphosphonates and 5'-methylphosphonates of sugar modified nucleosides, compositions and uses thereof |
WO1992000988A1 (en) * | 1990-07-13 | 1992-01-23 | Bodor Nicholas S | Targeted drug delivery via phosphonate derivatives |
Non-Patent Citations (23)
Title |
---|
"Intracellular metabolism and pharmacokinetics of 5'-hydrogenphosphonate of 3'-azido-2',3'-dideoxythymidine, a prodrug of 3'-azido-2',3'-dideoxythymidine", ANTIVIRAL RESEARCH, vol. 63, 2004, pages 107 - 113 |
ANTONELLI, G; TURRIZIANI, O.; VERRI, A.; NARCISO, P.; FERRI, F.; D'OFFIZI, G.; DIANZINI, F.: "Long-term exposure to zidovudine affects in vitro and in vivo the efficiency of thymidine kinase", AIDS RES HUM RETROVIR., vol. 12, 1996, pages 223 - 228 |
CASARA P.J. ET AL.: "Synthesis of acid stable 5'-O-fluoromethyl phosphanates of nucleosides. Evaluation as inhibitors of reverse transcriptase", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 2, no. 2, 1992, pages 145 - 148, XP008112220 * |
CHARIOT, P.; DROGOU, I.; DE LACROIX-SZMANIA, I.; ELIEZER-VANEROT, M.C.; CHAZAUD, B.; LOMBES, A.; SCHAEFFER, A.; ZAFRANI, E.S.: "Zidovudine-induced mitochondrial disorder with massive liver steanosis, myopathy, lactic acidosis, and mitochondrial DNA depletion", J. HEPATOL., vol. 30, 1999, pages 156 - 160 |
DATABASE CA [online] ORLOV V.M. ET AL.: "Investigation of nucleoside and nucleotide derivatives by plasma desorption mass spectrometry", XP008112355, accession no. STN Database accession no. 121:7716 * |
DATABASE CA [online] SHIROKOVA E.A. ET AL.: "Uncharged AZT and D4T Derivatives of Phosphonoformic Phosphonoformic and Phosphonoacetic Acids as Anti-HIV Pronucleosides", XP008112392, accession no. STN Database accession no. (141:140705) * |
DATABASE CHEMCATS [online] 9 August 2004 (2004-08-09), XP008112398, accession no. STN Database accession no. (RN 724696-86-0) * |
DE CLERCQ, E.: "New development in anti-HIV chemotherapy", BIOCHIM. BIOPHYS. ACTA, vol. 1587, 2002, pages 258 - 275 |
DYATKINA N.B. ET AL.: "Sintez 5'-ftoralkilfosfonatov nukleozidov-soedineny s potentsialnymi protivovirusnymi svoistvami", BIOORGANICHESKAYA KHIMIYA, vol. 18, no. 1, 1992, MOSCOW, pages 100 - 105, XP008112333 * |
GROSCHEL, B.; CINATL, J.H.; CINATL J. JR.: "Viral and cellular factors for resistance against anti-retroviral agents", INTERVIROLOGY, vol. 40, 1997, pages 400 - 407 |
JOURNAL OF MEDICINAL CHEMISTRY, vol. 47, no. 14, 11 August 2004 (2004-08-11), pages 3606 - 3614 * |
KELLAM, P.; BOUCHER, C.A.; LARDER, B.A.: "Fifth mutations in HIV reverse transcriptase contributes to the development of high level resistance to zidovudine", PROC. NATL. ACAD. SCI. U.S.A, vol. 89, 1992, pages 1934 - 1938 |
KRAEVSKY A. ET AL.: "Novye 5'-fosfonaty modifitsrovannykh po sakharnomy ostatku nukleosidov kak ingibitory produktsii VICH", MOLEKULYARNAYA BIOLOGIYA, vol. 28, no. 3, 1992, MOSCOW, pages 624 - 633, XP008112338 * |
KUKHANOVA M.K. ET AL.: "Gidroliz 5'-fosfonatov i fosfatov nykleozidov fosfatazami razlichnogo proiskhozhdeniya i syvorotkami krovi cheloveka I telenka", MOLEKULYARNAYA BIOLOGIYA, vol. 26, no. 5, 1992, MOSCOW, pages 1148 - 1159, XP008112336 * |
MAMAEVA O.A. ET AL.: "Izuchenie anti-HIV aktivnosti 5'-fosfonatov azidotimidina", MOLEKULYARNAYA BIOLOGIYA, vol. 28, no. 1, 1994, MOSCOW, pages 137 - 142, XP008112335 * |
MOL. BIOL., vol. 28, no. 3, 1994, MOSCOW, pages 708 - 713 * |
REN, J.; ESNOUF, R.M.; HOPKINS, A.L.; JONES, E.Y.; KIRBY, I.; KEELING, J.; ROSS, C.K.; LARDER, B.A.; STUART, D.I.; STAMMERS, D.K.: "3'-Azido-3'-deoxythymidine drug resistance mutations in HIV-1 reverse transcriptase can induce long range conformational changes", PROC. NATL. ACAD. SCI. U.S.A, vol. 95, 1998, pages 9518 - 9523 |
See also references of EP1829885A4 |
SHIROKOVA E.A. ET AL.: "Novye proizvodnye 3'-azido-3'dezoksitimidina i fosfonomuraviinoi kisloty", MOSCOW, BIOORGANICHESKAYA KHIMIYA, vol. 30, no. 3, May 2004 (2004-05-01) - June 2004 (2004-06-01), pages 273 - 280, XP008112334 * |
SOMOGYI G. ET AL.: "Metabolic properties of phosphonate esters", PHARMAZIE, vol. 59, no. 5, 12 November 2004 (2004-11-12), pages 378 - 381, XP008112292 * |
TARUSOVA N.B. ET AL.: "Ingibirovannye reproduktsii virusa immunodifitsita cheloveka v kulture kletok 5'-fosfonatami 3'-azido-2'3'-didezoksinukleozidov", MOLEKULYARNAYA BIOLOGIYA, vol. 23, no. 6, 1989, MOSCOW, pages 1716 - 1724, XP008112337 * |
Y. SKOBLOV ET AL., ANTIVIRAL RESEARCH, vol. 63, 2004, pages 107 - 113 |
YANYAREV D.V. ET AL.: "Aminokarbonilfosfonilnye proizvodnye 3'-azido-3'-dezoksitimidina kak potentsialnye anti-VICH preparaty. Materialy Mezhdunarodnoi konferentsii studentov i aspirantov po fundamentalnym naukam "Lomonosov 2003"", SEKTSIYA KHIMIYA, MOSCOW, IZD-VO KHIM. FAK. MGU, vol. 1, 15 April 2003 (2003-04-15) - 18 April 2003 (2003-04-18), pages 151 * |
Also Published As
Publication number | Publication date |
---|---|
CN101115765A (zh) | 2008-01-30 |
RU2322450C2 (ru) | 2008-04-20 |
EP1829885A4 (en) | 2013-07-10 |
EP1829885B1 (en) | 2015-07-15 |
US7999099B2 (en) | 2011-08-16 |
RU2004134388A (ru) | 2006-05-20 |
EP1829885A1 (en) | 2007-09-05 |
US20090111979A1 (en) | 2009-04-30 |
WO2006062434A8 (fr) | 2007-11-01 |
KR20070116580A (ko) | 2007-12-10 |
ES2550136T3 (es) | 2015-11-04 |
CN101115765B (zh) | 2012-10-10 |
KR101323698B1 (ko) | 2013-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107148424B (zh) | 用于诱导细胞因子的环状二核苷酸 | |
KR102656571B1 (ko) | 아르기나아제 억제제 | |
EP0642528B1 (fr) | Composes biologiquement actifs de type phosphotriesters | |
JP2020532532A (ja) | 化合物、組成物、及び疾患の治療方法 | |
Gerhart et al. | 2-(4-Amino-4-carboxybutyl) aziridine-2-carboxylic acid. A potent irreversible inhibitor of diaminopimelic acid epimerase. Spontaneous formation from. alpha.-(halomethyl) diaminopimelic acids | |
WO2014032481A1 (zh) | 一种替诺福韦前药及其在医药上的应用 | |
JP2005508305A (ja) | ガンマ/デルタt細胞を活性化するための有機リン化合物 | |
TW200844108A (en) | Compounds and pharmaceutical compositions for the treatment of liver disorders | |
EA019419B1 (ru) | Фосфонатные аналоги соединений ингибиторов вич, фармацевтическая композиция и набор, их включающие, и способ лечения нарушений, ассоциированных с вич | |
CN103764604A (zh) | 茋类似物和治疗癌症的方法 | |
Tatar et al. | Synthesis, characterization and screening of antimicrobial, antituberculosis, antiviral and anticancer activity of novel 1, 3-thiazolidine-4-ones derived from 1-[2-(benzoylamino)-4-(methylthio) butyryl]-4-alkyl/arylalkyl thiosemicarbazides | |
Mehellou et al. | An investigation into the anti-HIV activity of 2′, 3′-didehydro-2′, 3′-dideoxyuridine (d4U) and 2′, 3′-dideoxyuridine (ddU) phosphoramidate ‘ProTide’derivatives | |
AU607965B2 (en) | Use of nucleosides for the manufacture of medicament for treatment of diseases caused by retrovirus or hepatitis b virus | |
WO2006062434A1 (en) | Modified 5'- phosphonate azidothymidine-potential anti-viral preparations | |
JPH10502655A (ja) | ジヌクレオシド−5’,5’−ピロリン酸 | |
Gosselin et al. | 5′-Hydrogenphosphonates of anti-HIV nucleoside analogues revisited: controversial mode of action | |
RU2373218C2 (ru) | 5'-фосфорсодержащие производные 2',3'-дидезокси-3'-тиацитидина новые противовирусные агенты | |
RU2418795C2 (ru) | Производные диоксолана для лечения рака | |
RU2187509C1 (ru) | Производные 5'-h-фосфоната 3'-азидо-3'-дезокситимидина и фармацевтические композиции на их основе | |
RU2430104C1 (ru) | Новые депо-формы зидовудина и ламивудина на основе производных фосфоновых кислот | |
RU2430103C1 (ru) | Уретановые производные азт - потенциальные противовирусные препараты | |
RU2642426C1 (ru) | 1-Этил-6-фтор-4-оксо-7-(8-этокси-2-оксо-2Н-хромен-3-ил)-1,4-дигидрохинолин-3-карбоновая кислота, обладающая противотуберкулезной активностью | |
Schott et al. | Synthesis and in vitro anti-HIV activities of amphiphilic heterodinucleoside phosphate derivatives containing the 2', 3'-dideoxynucleosides ddC, AZT and ddI | |
RU2304145C1 (ru) | Ди- и триникотинаты глицирризиновой кислоты и ингибитор репродукции вируса иммунодефицита человека | |
RU2243972C1 (ru) | Фосфорамидаты нуклеозидных аналогов - ингибиторы репродукции вируса иммунодефицита человека |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077013688 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005763842 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580046745.0 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2005763842 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11720250 Country of ref document: US |